Adição na publicação
#15.35
10/13/2021
RPI 2649
Application data
Number
112019011627Type
Filing
Publication
PCT
US2017065270 The INPI issued a technical opinion on patentability. The applicant must respond for examination to continue.
Latest action published by the INPI: 10/13/2021. We update with every new RPI gazette, published weekly.
Applicants
LIXTE BIOTECHNOLOGY, INC.
US
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
US
Inventors
H. W. (pessoa física)
US
J. K. (pessoa física)
US
R. L. (pessoa física)
US
S. H. (pessoa física)
US
Z. Z. (pessoa física)
US
IPC Classification
Priority claims
US
62/465,001 · 02/28/2017
US
62/497,949 · 12/08/2016
US
62/545,373 · 08/14/2017
Abstract
A presente invenção refere-se a um método para tratar um indivíduo que sofre de câncer compreendendo administrar ao indivíduo uma quantidade eficaz de um inibidor de PP2A.
Publications in the Brazilian Industrial Property Gazette (RPI).
#15.35
10/13/2021
RPI 2649
#6.23
10/13/2021
RPI 2649
#1.3
11/12/2019
RPI 2549
#1.1
06/25/2019
RPI 2529
From the same holder
Same category
Patent monitoring
Receive alerts on INPI events, decisions, and expiry dates for your portfolio.